ОБОРОТ ТРОМБОЦИТОВ И АТЕРОТРОМБОЗ
https://doi.org/10.21518/2307-1109-2017-2-131-141
Аннотация
Тромбоциты играют ведущую роль в инициации атеротромбоза – образования внутрисосудистых тромбов в участках атеросклеротическом повреждении сосудов. Функциональная (протромботическая) активность тромбоцитов существенным образом варьирует как у здоровых лиц, так и у пациентов с сердечно-сосудистыми заболеваниями. Одной из причин повышения активности тромбоцитов может быть ускорение их продукции и оборота. При стимуляции тромбоцитопоэза в кровотоке появляются крупные и ретикулярные (с повышенным количеством РНК) «молодые» тромбоциты. Эти тромбоциты содержат больше адгезивных рецепторов, больше секреторных гранул и обладают повышенной способностью к агрегации. В обзоре приводятся данные, указывающие на то, что крупные и ретикулярные тромбоциты являются не только маркерами, но и предикторами атеротромботических событий, и в первую очередь острого коронарного синдрома. Увеличение количества таких тромбоцитов у больных, получающих антитромбоцитарные препараты, ассоциировано со снижением эффективности их антиагрегантного действия. Предполагается, что появление крупных и ретикулярных тромбоцитов в крови больных с атеросклерозом и атеротромбозом может быть следствием повышения тромбопоэтической активности мегакариоцитов при этих патологических состояниях.
Об авторе
А. В. МАЗУРОВ
Научный медицинский исследовательский центр кардиологии Минздрава России
Россия
д.м.н., профессор
Россия
д.м.н., профессор
Список литературы
1. Thompson CB, Jakubowsky JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood, 1988, 72: 1-8.
2. de Gaetano G, Santimone I, Gianfagna F. Iacoviello L, Cerletti C. Variability of platelet indices and function: acquired and genetic factors. In: Antiplatelet Agents, Handbook of Experimental Pharmacology (210) (eds. P. Gresele et al.), Springer-Verlag, Berlin Heidelberg, 2012: 395-434.
3. Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta J, Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost, 2015, 114: 459–468.
4. Yakushkin VV, Zyuryaev IT, Khaspekova SG, Sirotkina OV, Ruda MYa, Mazurov AV. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome. Platelets 2011, 22: 243-251.
5. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J6, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J, 2015, 36: 1762-1771.
6. Reny JL, Fontana P, Hochholzer W, Neumann FJ, Ten Berg J, Janssen PW, Geisler T, Gawaz M, Marcucci R, Gori AM, Cuisset T, Alessi MC, BerdaguО P, Gurbel PA, Yong G, Angiolillo DJ, Aradi D, Beigel R, Campo G, Combescure C. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb Haemost, 2016, 115: 844-855.
7. Larsen PD, Holley AS, Sasse A, Al-Sinan A, Fairley S, Harding SA. Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thromb Res, 2017, 152: 14-19.
8. Zucker-Franklin D. Megakaryocyte and platelet structure in thrombocytopoiesis: the effect of cytokines. Stem Cells, 1996, 14(Suppl 1): 1-17.
9. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest, 2005, 115: 3339–3347.
10. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol, 2006, 134: 453-466.
11. Italiano JE, Hartwig JH. Megakaryocyte development and platelet production. In Platelets. Third Edition (Ed. Michelson AD), Elsieveier, Academic Press. Amsterdam, Boston, London et al. 2015: 27-51.
12. Johnson AD. The Genetics of Common Variation affecting Platelet Development, Function and Pharmaceutical Targeting. Thromb Haemost, 2011, 9(Suppl 1): 246–257.
13. Shameer K, Denny JC, Ding K, Jouni H, Crosslin DR, de Andrade M, Chute CG, Peissig P, Pacheco JA, Li R, Bastarache L, Kho AN, Ritchie MD, Masys DR, Chisholm RL, Larson EB, McCarty CA, Roden DM, Jarvik GP, Kullo IJ. A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet, 2014, 133: 95-109.
14. Trowbridge EA, Reardon DM, Hutchinson D, Pickering C. The routine measurement of platelet volume: a comparison of light-scattering and aperture-impedance technologies. Clin Phys Physiol Meas, 1985, 6: 221–238.
15. Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA. The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol, 2012, 9: 658–670.
16. Kienast J, Schmitz G. Flow Cytometric Analysis of Thiazole Orange Uptake by Platelets: A Diagnostic Aid in the Evaluation of Thrombocytopenic Disorders. Blood, 1990, 75: 116-121.
17. Harrison P, Robinson MS, Mackie IJ, Machin SJ. Reticulated platelets. Platelets, 1997, 8: 379–383.
18. Kurata Y, Hayashi S, Kiyoi T, Kosugi S, Kashiwagi H, Honda S, Tomiyama Y. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol, 2001, 115: 656-664.
19. Bowles KM, Cooke LJ, Richards EM, Baglin TP: Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Haematol, 2005, 27: 370–373.
20. Khaspekova SG, Shustova ON, Golubeva NV, Vasiliev SA, Mazurov AV. Relationships of mean platelet volume and plasma thrombopoietin with glycocalicin levels in thrombocytopenic patients. Acta Haematologica, 2015, 133: 295–299.
21. Leytin V, Shapiro H, Novikov I, Radney J. Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes. Biochem Biophys Res Commun, 1996, 226: 94–100.
22. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. Am Coll Cardiol, 2008, 52: 743-749.
23. Mangalpally K, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis, 2010, 30: 251–262.
24. McBane II RD, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis, 2014, 37: 148–154.
25. Lador A,бLeshem Lev D,б Spectre G,бAbelow A,бKornowski R, Lev EI. Characterization of surface antigens of reticulated immature platelets. J Thromb Thrombolysis, 2017, 44: 291–297.
26. Armstrong PC, Hoefer T, Knowles RB, Tucker AT, Hayman MA, Ferreira PM, Chan MV, Warner TD. Newly formed reticulated platelets undermine pharmacokinetically short-lived antiplatelet therapies. Arterioscler Thromb Vasc Biol, 2017, 37: 949-956.
27. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost, 2008, 99: 930-935.
28. Grove El, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost, 2011, 9: 185-191.
29. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Thromb Haemost, 2010, 8: 148-156.
30. Sansanayudh N, Anothaisintawee T, Muntham D, McEvoyd M, Attia J, Thakkinstian A. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Intern J Cardiology, 2014, 175: 433–440.
31. Sansanayudh N, Numthavaj P, Muntham D, Yamwong S, McEvoy M, Attia J, Sritara P, Thakkinstian A. Prognostic effect of mean platelet volume in patients with coronary artery disease A systematic review and meta-analysis. Thromb Haemost, 2015, 114: 1299–1309.
32. Wang XY, Yu HY, Zhang YY, Wang YP, Feng XH, Li ZP, Du XJ, Gao W. Serial changes of mean platelet volume in relation to Killip Class in patients with acute myocardial infarction and primary percutaneous coronary intervention. Thromb Res, 2015, 135: 652- 658.
33. Higaki T, Kurisu S, Watanabe N, Ikenaga H, Shimonaga T, Iwasaki T, Mitsuba N, Ishibashi K, Dohi Y, Fukuda Y, Kihara Y. Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart Vessels, 2016, 31: 269-74.
34. Karpatkin S. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood, 1978, 51: 307-316.
35. Motovska Z, Ondrakova M, Bednar F, Knot J, Ulmana J, Maly M. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a “Real World” registry. Thromb Res, 2015, 135: 1093–1099.
36. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Expert Opin Pharmacother, 2015, 16: 1739-47.
37. Хаспекова. С.Г., Зюряев И.Т., Якушкин В.В., Наймушин Я.А., Сироткина О.В., Зайцева Н.О., Руда М.Я., Мазуров А.В. Средний объем тромбоцитов: взаимосвязи с агрегационной активностью тромбоцитов и уровнем экспрессии гликопротеинов IIb-IIIa и Ib. Биомед. Хим., 2014, 60: 94-108.
38. Мазуров А.В., Зюряев И.Т., Хаспекова С.Г., Якушкин В.В., Сироткина О.В., Руда М.Я. Факторы, влияющие на агрегационную активность тромбоцитов у больных с острым коронарным синдромом. Тер. Архив, 2014, 86: 83-89.
39. Khaspekova SG, Zyuryaev IT, Yakushkin VV, Sirotkina OV, Zaytseva NO, Ruda MYa, Panteleev MA, Mazurov AV. Relationships of glycoproteins IIb-IIIa and Ib content with mean platelet volume and their genetic polymorphisms. Blood Coagul Fibrinolysis, 2014, 25: 128-134.
40. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet, 1991, 338: 1409-1411.
41. Lai HM, Xu R, Yang YN, Ma YT, Li XM, Zhao Q, Chen QJ, Zhai H, Liu F, Chen BD. Association of mean platelet volume with angiographic thrombus burden and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv, 2015, 85(Suppl 1): 724-733.
42. Wasilewski J, Desperak P, Hawranek M, Ci_lak A, Osadnik T, Pyka _, Gawlita M, Bujak K, Niedziela J, Krawczyk M, G_sior M. Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study. Platelets, 2016, 27: 452-458.
43. Eisen A, Bental T, Assali A, Kornowski R, Lev EI. Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention. J Thromb Thrombolysis, 2013, 36: 469–474.
44. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39 531 participants from the general population. J Thromb Haemost, 2011, 9: 49–56.
45. Guthikonda S, Lev EI, Patel R, De Lao T, Bergeron AL, Dong JF, Kleiman NS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost, 2007, 5: 490-496.
46. Perl L, Lerman-Shivek H, Rechavia E, Vaduganathan M, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Codner P, Bental T, Battler A, Kornowski R, Lev EI. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial Infarction. J Am Coll Cardiol, 2014, 63: 513-517.
47. Eisen A, Lerman-Shivek H, Perl L, Rechavia E, LeshemLev D, Zemer-Wassercug N, Dadush O, Kazum S, Codner P, Kornowski R, Lev EI Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor. J Thromb Thrombolysis, 2015, 40: 70-75.
48. Vaduganathan M, Zemer-Wassercug N, Rechavia E, Lerman-Shivek H, Perl L, Leshem-Lev D, Orvin K, Kornowski R, Lev EI. Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. J Thromb Thrombolysis, 2015, 40: 211-217.
49. Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients Insights from the AMI-Florence 2 Study. Thromb Haemost, 2013, 109: 846–853.
50. Freynhofer MK, Iliev L, Bruno V, Rohla M, Egger F, Weiss TW, HЯbl W, Willheim M, Wojta J, Huber K. Platelet turnover predicts outcome after coronary intervention. Thromb Haemost, 2017, 117: 923–933.
51. Trowbridge EA, Slater DN, Kishk YT, Woodcock BW, Martin JF. Platelet production in myocardial infarction and sudden cardiac death. Thromb Haemost, 1984, 52: 167-71.
52. Bath PM, Gladwin AM, Carden N, Martin JF. Megakaryocyte DNA content is increased in patients with coronary artery atherosclerosis. Cardiovasc Res, 1994, 28: 1348-52.
53. Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, Edmonds M, Martin JF, Erusalimsky JD. Megakaryocyte Ploidy and Platelet Changes in Human Diabetes and Atherosclerosis. Arterioscl Thromb Vasc Biol, 1997, 17: 802-807.
54. Sinzinger H, Virgolini I, Fitscha P. Platelet kinetics in patients with atherosclerosis. Thromb Res, 1990, 57: 507-516.
55. Senaran H, Ileri M, Altinba_ A, Ko_ar A, Yetkin E, OztЯrk M, Karaaslan Y, Kirazli S. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol, 2001, 24: 405-408.
Рецензия
Для цитирования:
МАЗУРОВ А.В. ОБОРОТ ТРОМБОЦИТОВ И АТЕРОТРОМБОЗ. Атеротромбоз. 2017;(2):131-141. https://doi.org/10.21518/2307-1109-2017-2-131-141
For citation:
MAZUROV A.V. PLATELET TURNOVER AND ATHEROTHROMBOSIS. Aterotromboz = Atherothrombosis. 2017;(2):131-141. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-131-141
Просмотров: 852
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 